Epitope Diagnostics Launches Fully Automated Chemiluminescent Immunoassay Analyzers

February 24, 2023

Epitope Diagnostics, Inc. has officially launched its fully automated chemiluminescent immunoassay analyzers (ECL25 and ECL100) together with panel kits of routine and niche chemiluminescence immunoassay tests covering different clinical areas. Please check our advert on the Clinical Chemistry Journal Volume 69 Issue 2 from February 2023.

See Advert →

Upcoming Events

Düsseldorf​​​​​​​, Germany
November 13 - 16, 2023
Medlab Middle East 2024
Dubai, UAE
​​​​​​​February 5 - 8, 2024

New Version of Fecal Sample Collection Tube!

September 19, 2022

Fecal sample is used for many clinical laboratories test in disease diagnosis and monitoring. The most popular tests include Fecal Occult Blood test, fecal Calprotectin test, fecal Pancreatic Elastase 1 test, fecal Helicobacter pylori antigen test, fecal Giardia and cryptosporidium antigen tests, etc. However, unlike serum and plasma-based test, fecal sample requires collection and extraction before testing. The tradition way of accurate fecal sample collection extraction involves weighing stool on an analytical scale and extracted with a volume of buffer. Epitope Diagnostics has invented a Stool Sample Quantitative Collection and Extraction Device (sQED, US Patent issued). This sQED provide convenient and accurate collection and extraction of stool specimen without the traditional weighing process. Moreover, this device standardizes the collection process and the extracted sample can be directly used for automated immunoassay system.
Epitope Diagnostics Inc, is excited to announce our new version of fecal sample collection tube!Epitope Diagnostics Inc, is excited to announce our new version of fecal sample collection tube!

Epitope Diagnostics Introduces Immunoassay Kits for Detection of COVID-19

March 3, 2020

Epitope Diagnostics has proudly introduced immunoassay kits exclusively for the qualitative detection of COVID-19. These kits include The EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit and EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit. With proven results from clinical testing in China, Epitope Diagnostics, Inc. is eager to cooperate and collaborate to combat the current COVID-19 situation.

Read More →

Epitope Diagnostics Inc. joins MetroConnect to expand international growth

September 27, 2018

Epitope Diagnostics pleased to announce it has been selected to take part in MetroConnect 2018, an export assistance program run by the World Trade Center San Diego (WTC) and designed to help San Diego companies accelerate their global growth.
Read More →

New Anti-Müllerian Hormone ELISA Kit Launched

December 29, 2017

Anti-Müllerian hormone (AMH) is uniquely produced by granulosa cells of ovarian follicles during folliculogenesis. It is currently the best measure of ovarian reserve in the clinical setting and may also be used to predict ovarian response in IVF and to monitor patients with a history of granulosa cell tumors.

Read More →

Study Spotlight: Chromogranin A as a Potential Prognostic Marker for CRPC Patients

February 11, 2016

Epitope Diagnostics’ EDI Human Chromogranin A ELISA Kit was recently used by a research group lead by Dr. Ugo De Giorgi to publish two key papers highlighting another aspect of the relationship between chromogranin A (CgA) and prostate cancer. 

Read More →

Epitope Diagnostics Launches a Novel 25-OH Vitamin D ELISA Kit

May 11, 2015

Epitope Diagnostics, Inc. has launched a novel CE marked ELISA kit to measure total 25-Hydroxy Vitamin D2 and D3.

Vitamin D is a compound that is essential to the human body. Insufficiency and deficiency increases the risk of bone fractures and debilitating bone related disease, such as osteoporosis.

Read More →

Epitope Diagnostics, Inc. Introduces New 2-Hour Human ACTH ELISA Kit

August 18, 2014

Epitope Diagnostics is proud to introduce a new adrenocortocotropic hormone (ACTH) ELISA Kit, which measures ACTH levels with high sensitivity and robust assay performance characteristics.

Read More →

EDI Launches New Anti-Auristatin Monoclonal Antibodies and ELISA Kits

August 6, 2014

Epitope Diagnostics is proud to announce that a new set of monoclonal antibodies specific to auristatins is now commercially available. The novel clones are specific against detecting monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF), two anti-cancer compounds. Using these new monoclonal antibodies, we were able to successfully develop highly sensitive MMAE-ADC and MMAF-ADC ELISA kits.